| 20/03/26 | 07:00:06 | 20 Mar 2026 | | Transaction in Own Shares |
| 19/03/26 | 12:00:00 | 19 Mar 2026 | | Lynavoy (linerixibat) approved by US FDA |
| 19/03/26 | 07:00:09 | 19 Mar 2026 | | Transaction in Own Shares |
| 18/03/26 | 15:30:01 | 18 Mar 2026 | | Director/PDMR Shareholding |
| 18/03/26 | 07:00:06 | 18 Mar 2026 | | Transaction in Own Shares |
| 17/03/26 | 15:30:01 | 17 Mar 2026 | | Director/PDMR Shareholding |
| 17/03/26 | 07:00:05 | 17 Mar 2026 | | Transaction in Own Shares |
| 16/03/26 | 07:00:09 | 16 Mar 2026 | | Transaction in Own Shares |
| 13/03/26 | 10:31:23 | 13 Mar 2026 | | US FDA approves Arexvy for adults 18-49 AIR |
| 13/03/26 | 07:00:03 | 13 Mar 2026 | | Transaction in Own Shares |
| 12/03/26 | 15:30:00 | 12 Mar 2026 | | Director/PDMR Shareholding |
| 12/03/26 | 07:00:05 | 12 Mar 2026 | | Transaction in Own Shares |
| 11/03/26 | 07:00:03 | 11 Mar 2026 | | Transaction in Own Shares |
| 10/03/26 | 07:00:06 | 10 Mar 2026 | | Transaction in Own Shares |
| 09/03/26 | 15:00:00 | 9 Mar 2026 | | Board Committee Change |
| 09/03/26 | 07:00:14 | 9 Mar 2026 | | GSK and Alfasigma agree global linerixibat rights |
| 09/03/26 | 07:00:07 | 9 Mar 2026 | | Transaction in Own Shares |
| 06/03/26 | 14:21:19 | 6 Mar 2026 | | Filing of GSK plc 2025 Annual Report on Form 20-F |
| 06/03/26 | 07:00:05 | 6 Mar 2026 | | Transaction in Own Shares |
| 05/03/26 | 10:00:00 | 5 Mar 2026 | | GSK publishes Annual Report 2025 |
| 05/03/26 | 07:00:05 | 5 Mar 2026 | | Transaction in Own Shares |
| 04/03/26 | 15:30:00 | 4 Mar 2026 | | Director/PDMR Shareholding |
| 04/03/26 | 07:00:05 | 4 Mar 2026 | | Transaction in Own Shares |
| 03/03/26 | 15:00:00 | 3 Mar 2026 | | GSK completes acquisition of RAPT Therapeutics |
| 03/03/26 | 07:00:05 | 3 Mar 2026 | | Transaction in Own Shares |
| 02/03/26 | 15:00:00 | 2 Mar 2026 | | Total Voting Rights |
| 02/03/26 | 07:00:07 | 2 Mar 2026 | | Transaction in Own Shares |
| 27/02/26 | 15:30:00 | 27 Feb 2026 | | Director/PDMR Shareholding |
| 27/02/26 | 07:00:06 | 27 Feb 2026 | | Transaction in Own Shares |
| 26/02/26 | 07:05:00 | 26 Feb 2026 | | Linerixibat accepted for priority review in China |
| 26/02/26 | 07:00:11 | 26 Feb 2026 | | Bepirovirsen accepted for Japan regulatory review |
| 26/02/26 | 07:00:04 | 26 Feb 2026 | | Transaction in Own Shares |
| 25/02/26 | 16:54:33 | 25 Feb 2026 | | Director/PDMR Shareholding |
| 25/02/26 | 15:30:00 | 25 Feb 2026 | | Director/PDMR Shareholding |
| 25/02/26 | 07:00:06 | 25 Feb 2026 | | GSK enters agreement to acquire 35Pharma |
| 25/02/26 | 07:00:04 | 25 Feb 2026 | | Transaction in Own Shares |
| 24/02/26 | 15:30:00 | 24 Feb 2026 | | Director/PDMR Shareholding |
| 24/02/26 | 07:00:03 | 24 Feb 2026 | | Transaction in Own Shares |
| 23/02/26 | 07:00:10 | 23 Feb 2026 | | Transaction in Own Shares |
| 20/02/26 | 15:30:00 | 20 Feb 2026 | | Director/PDMR Shareholding |
| 20/02/26 | 07:00:03 | 20 Feb 2026 | | Transaction in Own Shares |
| 19/02/26 | 15:30:00 | 19 Feb 2026 | | Director/PDMR Shareholding |
| 19/02/26 | 07:00:04 | 19 Feb 2026 | | Transaction in Own Shares |
| 18/02/26 | 07:00:03 | 18 Feb 2026 | | Transaction in Own Shares |
| 17/02/26 | 15:30:00 | 17 Feb 2026 | | Director/PDMR Shareholding |
| 17/02/26 | 15:30:00 | 17 Feb 2026 | | Director/PDMR Shareholding |
| 17/02/26 | 07:00:09 | 17 Feb 2026 | | GSK - fourth tranche of share buyback programme |
| 17/02/26 | 07:00:02 | 17 Feb 2026 | | Exdensur approved by the European Commission |
| 16/02/26 | 15:30:00 | 16 Feb 2026 | | Director/PDMR Shareholding |
| 16/02/26 | 15:30:00 | 16 Feb 2026 | | Director/PDMR Shareholding |